Related Articles
Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancer
EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy
Effect of hydrothorax EGFR gene mutation and EGFR‑TKI targeted therapy on advanced non‑small cell lung cancer patients
A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy